Switching to Low Neurotoxic Antiretrovirals to Improve Neurocognition Among People Living With HIV-1-Associated Neurocognitive Disorder: The MARAND-X Randomized Clinical Trial.
Lazzaro A, Vai D, Barco A, Stroffolini G, Pirriatore V, Guastamacchia G, Nigra M, Ghisetti V, Tettoni MC, Noce G, Giaccone C, Trunfio M, Trentalange A, Bonora S, Di Perri G, Calcagno A.
Lazzaro A, et al. Among authors: nigra m.
J Acquir Immune Defic Syndr. 2024 Oct 1;97(2):180-191. doi: 10.1097/QAI.0000000000003480.
J Acquir Immune Defic Syndr. 2024.
PMID: 39250652
Clinical Trial.